Chemical formula: C₁₃H₁₇N₅O₈S₂ Molecular mass: 435.433 g/mol PubChem compound: 5742832
Aztreonam exhibits activity in vitro against gram-negative aerobic pathogens, including P. aeruginosa. Aztreonam binds to penicillin-binding proteins of susceptible bacteria, which leads to inhibition of bacterial cell wall synthesis, followed by filamentation and cell lysis.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J01DF01 | Aztreonam | J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DF Monobactams |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| AZACTAM Powder for solution for injection or infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| CAYSTON Powder and solvent for nebuliser solution | European Medicines Agency (EU) | MPI, EU: SmPC |
Aztreonam is an active ingredient of these brands:
United States (US)Canada (CA)
Croatia (HR)
Cyprus (CY)
Estonia (EE)
Finland (FI)Israel (IL)
Japan (JP)Lithuania (LT)
Malta (MT)Netherlands (NL)
New Zealand (NZ)Poland (PL)
Singapore (SG)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
